Scientists have got success with a new injection of HIV. Taking this injection once a year can reduce the risk of HIV ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...

Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

The United States’ shutdown of HIV/Aids funding may harm global Aids programmes irreparably, jeopardising millions of lives ...

Two more people have been potentially cured of HIV after receiving stem cell transplants to treat blood cancer or bone marrow ...

Merck's DOR/ISL met primary efficacy and safety goals in two Phase 3 HIV trials. Marketing applications are planned for ...

Researchers led by Imperial have unveiled primary trial results that show encouraging advances in HIV treatment driven by ...

The advent of effective antiretroviral therapy (ART) has increased the lifespan of many people living with HIV. As a result, ...

Incident HCV infection more than doubled among HIV-positive MSM with no history of injection drug use between 1995 and 2023.

To reduce care disparities and prevent them from exacerbating among people living with HIV who have long COVID, education and ...